Trop2 deal heats up antibody–drug conjugate space in cancer

被引：0
|
作者：
Catherine Shaffer
机构：
来源：
Nature Biotechnology | 2021年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Gilead’s $21 billion gamble is a dramatic shot to secure a promising first-in-class oncology drug.
引用
收藏
页码：128 / 130
页数：2
相关论文
共 50 条
  • [21] Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer
    Ma, F.
    Qiu, F.
    Tong, Z.
    Wang, J.
    Shi, Y.
    Zhang, Y.
    Yu, G.
    Shi, H.
    Wu, X.
    Liu, A.
    Zhang, Y.
    Wang, H.
    Cheng, Y.
    Yang, H.
    Li, H.
    Chang, J.
    Xing, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S361 - S362
  • [22] Design and synthesis of novel site-specific antibody-drug conjugates that target TROP2
    Luo, Caili
    Ren, Anni
    Jin, Zixuan
    Zhang, Jianxin
    Shi, Wei
    Zeng, Yue
    Liu, Zhaojun
    Lu, Mengru
    Hou, Yajing
    Tang, Feng
    Huang, Wei
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 110
  • [23] A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo
    Lin, Hong
    Zhang, Huiling
    Wang, Jun
    Lu, Meiping
    Zheng, Feng
    Wang, Changjun
    Tang, Xiaojun
    Xu, Ning
    Chen, Renjie
    Zhang, Dawei
    Zhao, Ping
    Zhu, Jin
    Mao, Yuan
    Feng, Zhenqing
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (05) : 1239 - 1249
  • [24] TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
    Hegedues, Luca
    Okumus, Oezlem
    Mairinger, Fabian
    Ploenes, Till
    Reuter, Sebastian
    Schuler, Martin
    Welt, Anja
    Vega-Rubin-de-Celis, Silvia
    Theegarten, Dirk
    Bankfalvi, Agnes
    Aigner, Clemens
    Hegedues, Balazs
    LUNG CANCER, 2023, 178 : 237 - 246
  • [25] Targeting Trop2 for treatment of prostate and breast cancer
    Stoyanova, Tanya
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [26] OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile
    Shia, Chi-Sheng
    Wen, Shih-Ni
    Hsu, Ren-Yu
    Tu, Jyy-Shiuan
    Chang, Hui-Wen
    Li, Wan-Fen
    Lai, Ming-Tain
    CANCER RESEARCH, 2024, 84 (06)
  • [27] Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors
    Wang, Jiani
    Tong, Zhongsheng
    Tan, Yinuo
    Shi, Yehui
    Wu, Yun
    Zhou, Qing
    Xing, Xiaoyan
    Chen, Xiaomei
    Qiu, Fuming
    Ma, Fei
    CELL REPORTS MEDICINE, 2024, 5 (09)
  • [28] Clinical significance of TROP2 expression in colorectal cancer
    Ohmachi, Takahiro
    Tanaka, Fumiaki
    Mimori, Koshi
    Inoue, Hiroshi
    Yanaga, Katsuhiko
    Mori, Masaki
    CLINICAL CANCER RESEARCH, 2006, 12 (10) : 3057 - 3063
  • [29] Shed Trop2 drives prostate cancer progression and Trop2 is a novel tissue prognostic biomarker and a candidate urinary marker for prostate cancer
    Liu, Shiqin
    Hawley, Sarah
    Kunder, Christian
    Hsu, En-Chi
    Shen, Michelle
    Aslan, Merve
    Marques, Fernando J.
    Lee, Chung S.
    Bermudez, Abel
    Westphalen, Lennart
    Auman, Heidi
    Newcomb, Lisa F.
    Lin, Daniel W.
    Nelson, Peter S.
    Feng, Ziding
    Tretiakova, Maria S.
    True, Lawrence D.
    Vakar-Lopez, Funda
    Carroll, Peter R.
    Simko, Jeffry
    Gleave, Martin E.
    Troyer, Dean A.
    McKenney, Jesse K.
    Peehl, Donna
    Pitteri, Sharon J.
    Brooks, James D.
    Liss, Michael A.
    Stoyanova, Tanya
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/β-catenin positive feedback loop
    Tang, Wenjuan
    Hu, Yu
    Tu, Kaihui
    Gong, Zhengyan
    Zhu, Man
    Yang, Tianfeng
    Sarwar, Ammar
    Dai, Bingling
    Zhang, Dongdong
    Zhan, Yingzhuan
    Zhang, Yanmin
    JOURNAL OF ADVANCED RESEARCH, 2024, 58 : 193 - 210
12345